Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
5/31/26 Revolution Medicines (RVMD) daraxonrasib for Pancreatic Cancer Subscribers Only Subscribers Only Subscribers Only
5/31/26 Akeso (9926) Idafang for Non-Small Cell Lung Cancer (NSCLC) Subscribers Only Subscribers Only Subscribers Only
5/31/26 Jiangsu Hengrui Pharmaceuticals (600276:SS) Avida for Colorectal Cancer (CRC) Subscribers Only Subscribers Only Subscribers Only
5/30/26 Pfizer (PFE) Talzenna for Prostate Cancer Subscribers Only Subscribers Only Subscribers Only
5/30/26 Pfizer (PFE) Aidexi for Gastric Cancer Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/26/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
09/08/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
09/17/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update